Announced
Synopsis
Ampersand Capital-backed Nexelis, a provider of assay development and advanced laboratory testing, agreed to acquire ImmunXperts, a biotechnology company. Financial terms were not disclosed. "ImmunXperts' immunology testing expertise will help Nexelis more broadly serve the needs of our customers. Nexelis will now have an unrivaled ability to efficiently develop immunogenicity assays, qualify and validate them in a regulated environment, and then ultimately perform them utilizing our high-throughput platforms in support of clinical trials," Benoit Bouche, Nexelis President and CEO.
Principals
Show Details & Financials
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.